marketreader

Ivy Leaguer biologist and pharma executive. All my opinions are BIASED, not investment advice! Do your own critical thinking and DD.

[marketreader @marketreader8]

Fire $AFMD CEO Adi! 4 CMO plus 1 CSO leaving in 5 years, proving that CEO is either incompetent at hiring the right people or at managing people. Plus the delays and bad timing of raising funds. Share price also tells that he failed. The board needs to fire him, or be replaced.

[Season1103 @Season11031]

$GME $AMC style short squeeze: A big $AFMD holder might file SEC soon: Volume was so weak no one could have bought a large % of $AFMD without notice. Today > entire float be traded, so a fund can buy up more than 50% of float then create an epic short squeeze to $100/share.

[marketreader @marketreader8]

@RayLagunabb @zen_tropy @BrianUherek @EmmerdeurElizA @affimed A CEO with an MD not understanding the imaging data from a trial patient without any expert help is shocking to me. Plus 4 CMO plus 1 CSO left $AFMD in 5 years, proving that he is either incompetent at hiring the right people or at managing people.

[marketreader @marketreader8]

@RayLagunabb @zen_tropy @BrianUherek @EmmerdeurElizA @affimed I knew $AFMD was in trouble when former CEO Adi admitted in an interview article (years ago, forgot which one) that he didn’t understand the breaking result from the first responder in the AFM13 and NK combo at MD Anderson, needed the MD Anderson professor to explain the result.

[marketreader @marketreader8]

@ANACONDAFINANC1 @ny1972_47 @dhovekamp42 @Getoutofmyway1 Why did they stop it! What DOR do you think the big pharmas will require to sign a codevelopment deal with $AFMD?

[marketreader @marketreader8]

@ny1972_47 @dhovekamp42 @Getoutofmyway1 I don’t remember the DOR in $AFMD AFM13-Keytruda combo trial. Do you know? What DOR do you expect from the 24-PDL1 combo?

[marketreader @marketreader8]

@ny1972_47 @Biotech777 @affimed Thanks!

[marketreader @marketreader8]

@ny1972_47 @Biotech777 @affimed Medarex was my largest holding when Pien sold it. I do hope no one steal away $AFMD like Medarex. @ny1972_47 What market cap do you think Medarex would be worth today if still independent? What market cap do you estimate $AFMD will have if both AFM24 and AFM13 approved?

[marketreader @marketreader8]

@ny1972_47 @Biotech777 @affimed Glad to hear anyone who remembers Medarex, whose CEO Howard Pien is even more incompetent than $AFMD’s Adi. Pien sold Medarex for 2.4 billion to BMS. Nivolumab 10B sales in 2022, ipilimumab 1.9B sales in 2021. Both owned by Medarex.

[marketreader @marketreader8]

@ny1972_47 @rinnowardana @ny1972_47 Hey, what’s your background? I don’t understand why Baker brothers or Cohen Point72 don’t increase their stake in $AFMD at this valuation. Am I missing something that they saw? PM me if you prefer

[marketreader @marketreader8]

@ny1972_47 @zen_tropy @affimed @ArtivaBio Your question cannot be answered in a short paragraph here.

[marketreader @marketreader8]

@zen_tropy @BrianUherek Mice not = patients. Their readouts in patients are somewhat circumstantial. More clinical data are needed. At least this may not be applicable to all types of solid tumors. AFM24 did have effects as a mono therapy for lung cancer, which is what $AFMD is targeting now in combo.

[marketreader @marketreader8]

Told you so more than 4 years ago! If $AFMD had fired Adi 4 years ago, $AFMD would be in the 20s today.

[marketreader @marketreader8]

Fire $AFMD CEO Adi! 4 CMO plus 1 CSO leaving in 5 years, proving that CEO is either incompetent at hiring the right people or at managing people. Plus the delays and bad timing of raising funds. Share price also tells that he failed. The board needs to fire him, or be replaced.

[marketreader @marketreader8]

Fire $AFMD CEO Adi! 4 CMO plus 1 CSO leaving in 5 years, proving that CEO is either incompetent at hiring the right people or at managing people. Plus the delays and bad timing of raising funds. Share price also tells that he failed. The board needs to fire him, or be replaced.

[marketreader @marketreader8]

@BrianUherek @FrankHulskof Let’s see if $AFMD will rise 50% by the end of today!

[marketreader @marketreader8]

@BrianUherek @FrankHulskof The day Steve Ballmer resigned from Microsoft, its share price rose 5%. The day Adi is gone from $AFMD, its price will likely rise 50%. Adi actually looks a bit like Steve

[marketreader @marketreader8]

@BrianUherek @FrankHulskof The day Steve Ballmer resigned from Microsoft, its share price rose 5%. The day Adi is gone from $AFMD, its price will likely rise 50%. Adi actually looks a bit like Steve

[Mark Cuban @mcuban]

Let me help you out and give you my thoughts on DEI
1. Diversity
Good businesses look where others don't, to find the employees that will put your business in the best possible position to succeed.
You may not agree, but I take it as a given that there are people of various races, ethnicities, orientation, etc that are regularly excluded from hiring consideration. By extending our hiring search to include them, we can find people that are more qualified. The loss of DEI-Phobic companies is my gain.

1a. We live in a country with very diverse demographics. In this era where trust of businesses can be hard to come by, people tend to connect more easily to people who are like them. Having a workforce that is diverse and representative of your stakeholders is good for business.

[Elon Musk @elonmusk]

@mcuban Cool, so when should we expect to see a short white/Asian women on the Mavs?

[Elon Musk @elonmusk]

DEI is just another word for racism. Shame on anyone who uses it.

[marketreader @marketreader8]

@RayLagunabb @RNA_Biotech $AFMD is the real McCoy, $NKTX has a better CEO. If $AFMD had $NKTX CEO, it would be in the 20s now.